{"product_id":"amyris-balanced-scorecard","title":"Amyris Balanced Scorecard","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Amyris Balanced Scorecard Analysis gives you a structured view of the company’s financial, customer, internal process, and learning and growth priorities. This page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to access the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eB\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eenefits\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Yield Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA portfolio-yield focus would force Amyris technical teams to rank the top 15 highest-value molecules, so lab spend stays tied to the best commercial scale-up odds. Amyris does not publish FY2025 operating data after its 2023 Chapter 11, so the scorecard should use current molecule-level value, not stale revenue history. That keeps R\u0026amp;D linked to 2026 sales targets and cuts work on low-return programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic B2B Alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter Amyris's 2023 restructuring, the customer view shifts from consumer sales to 5 industrial partners, so success is measured by renewal, volume, and margin, not brand traffic. That matters because global fragrance and flavor accounts are long-cycle and sticky, which helps protect cash. Amyris has no public 2025 fiscal-year operating data, so partner retention is the clearest scorecard metric.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Lab Velocity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInternal lab velocity shortens Amyris’s path from DNA design to pilot fermentation, cutting the molecule development window by nearly 18 months. Faster strain engineering also raises lab throughput, so more candidates reach test phase with less rework. That speed lowers time-to-value and supports tighter R\u0026amp;D capital use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnit Economic Precision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUnit economic precision shows the exact cost per liter for fermented ingredients across 3 production sites, so Amyris can spot yield gaps, energy waste, and downtime fast.\u003c\/p\u003e\n\u003cp\u003eThat granularity matters when investors want proof that a 30% margin can hold under scale, since even a $0.10 per liter swing can change gross profit quickly.\u003c\/p\u003e\n\u003cp\u003eIt also helps management compare sites on the same basis and steer output to the lowest-cost line without guessing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eESG Credibility Benchmarking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eESG credibility benchmarking gives Amyris a hard-data proof point: measured carbon intensity, not marketing claims. In beauty, Scope 3 emissions can make up more than 70% of a brand’s footprint, so even small upstream cuts matter to partners.\u003c\/p\u003e\n\u003cp\u003eWhen Amyris shows lower kg CO2e per unit than petroleum-derived inputs, it can support ESG bids with numbers buyers can audit. That is a real selling point for luxury and cosmetics brands facing tighter 2025 disclosure pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris: Focused R\u0026amp;D, Stronger Partners, Cleaner ESG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenefits: Amyris’s scorecard keeps R\u0026amp;D tied to the 15 highest-value molecules, so capital stays on programs with the best scale-up odds. Post-2023 Chapter 11, partner retention and volume become the main growth signals, which is cleaner than old consumer metrics. Site-level unit economics and measured kg CO2e per unit help management cut waste and win audited ESG bids.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eBenefit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e15 molecules\u003c\/td\u003e\n\u003ctd\u003eFocus lab spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 partners\u003c\/td\u003e\n\u003ctd\u003eTrack renewals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ekg CO2e\/unit\u003c\/td\u003e\n\u003ctd\u003eSupport ESG bids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOutlines how Amyris performs across the four core Balanced Scorecard perspectives\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Amyris Balanced Scorecard snapshot to quickly identify and address financial, customer, process, and growth pain points.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erawbacks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Bankruptcy Cash Bias\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris’s post-bankruptcy scorecard tilts toward survival: with no 2025 operating filing after its collapse, liquidity became the priority, not long-horizon R\u0026amp;D. That cash bias can crowd out platform research and leave a shallow pipeline, where near-term molecules win over next-generation breakthroughs.\u003c\/p\u003e\n\u003cp\u003eThe risk is clear: in 2023, Amyris posted $276.4 million of cash and cash equivalents at year-end, but still lacked durable funding for multi-year science.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigid Biological Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigid Balanced Scorecard KPIs can miss synthetic biology’s real noise: one failed fermentation run may reflect biology, not bad execution. Amyris’ scale-up pain shows why this matters; the Company Name filed Chapter 11 in 2023 after years of losses, including a $1.3 billion accumulated deficit. When biology is uncertain, fixed targets can punish valid R\u0026amp;D risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFeedstock Pricing Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFeedstock pricing volatility is a clear gap in Amyris’s balanced scorecard because Brazilian sugarcane costs can spike overnight, but the scorecard only updates after the hit shows up in margins. That lag matters: if feedstock costs rise 10% to 20%, cash gross margin can compress before internal KPIs catch up. By 2025, Amyris had no fresh public FY2025 operating data after its bankruptcy, which makes real-time commodity tracking even more important.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Integration Friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eData integration friction is a real drawback for Amyris because lab gains do not flow cleanly into finance. In the 2026 model, a titer lift of even 1 point can be delayed by 1 to 2 quarters before it shows up in gross margin, cash burn, or EPS-style guidance. That gap makes quarterly forecasts error-prone, especially when inventory, batch yield, and revenue timing move at different speeds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner Dependence Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA scorecard built around a few large B2B partners can hide concentration risk: if one account slips, Amyris loses a big share of sales fast. That can push leaders to optimize for a narrow set of contracts, instead of building a wider base across faster-moving biotech niches. In Amyris, this matters because partner-heavy models can delay signals from smaller markets where growth is often faster and less dependent on one buyer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris’s Scorecard Missed the Warning Signs: Liquidity, R\u0026amp;D, and Sales Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris’s Balanced Scorecard has three clear drawbacks: liquidity pressure can crowd out R\u0026amp;D, fixed KPIs can misread fermentation setbacks, and partner concentration can hide sales risk. The Company Name’s 2023 Chapter 11 and $1.3 billion accumulated deficit show how fast those gaps can matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$276.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccumulated deficit\u003c\/td\u003e\n\u003ctd\u003e$1.3 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 filing\u003c\/td\u003e\n\u003ctd\u003eNo public data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmyris Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the same Amyris Balanced Scorecard analysis document you’ll receive after purchase—no sample, no placeholders, just the real file. The preview below is pulled directly from the full report, so you know exactly what you’re getting. Unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SOAR Analysis","offers":[{"title":"Default Title","offer_id":52934329336155,"sku":"amyris-balanced-scorecard","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/6857\/8907\/files\/amyris-balanced-scorecard.webp?v=1778310749","url":"https:\/\/soar-analysis.com\/products\/amyris-balanced-scorecard","provider":"SOAR Analysis","version":"1.0","type":"link"}